Phio Pharma stock maintains buy rating as cancer trial advances

H.C. Wainwright has reiterated a Buy rating and $14.00 price target for Phio Pharma (PHIO), citing promising advancements in its PH-762 Phase 1b clinical trial for skin cancers. The Safety Monitoring Committee approved dose escalation to cohort 5, affirming the treatment's favorable safety profile, while prior cohorts demonstrated significant efficacy, including complete responses in some cutaneous squamous cell carcinoma patients. With a strong financial position and recent strategic executive appointments, Phio is advancing PH-762 as a potential non-surgical treatment, with full trial enrollment anticipated by Q3 2025 and further data expected by H1 2026.

Analysis

Phio Pharma (NASDAQ:PHIO) has received a significant vote of confidence from H.C. Wainwright, which reiterated a Buy rating and a $14.00 price target, implying substantial upside from its current $2.17 price. This bullish stance is primarily supported by positive developments in the Phase 1b trial of its lead candidate, PH-762, for skin cancers. The Safety Monitoring Committee's recommendation to proceed with dose escalation to a fifth cohort underscores the treatment's favorable safety profile, with no dose-limiting toxicities or serious adverse events reported to date. Early efficacy signals are also promising; data from the first three cohorts showed that four of nine cutaneous squamous cell carcinoma (cSCC) patients achieved a pathologic complete response. Financially, the company appears stable for its stage, with InvestingPro data indicating a balance sheet holding more cash than debt and liquid assets sufficient to cover short-term liabilities. Despite a 20.56% year-to-date gain, the company's market capitalization remains low at $10.34M, positioning it as a high-risk, high-reward micro-cap biotech. Key upcoming catalysts include the completion of trial enrollment, projected for Q3 2025, and the potential release of additional data in the first half of 2026.

Key Decisions for Investors

• Given the strong early-stage clinical data for PH-762 and the significant analyst price target, investors with a high risk tolerance may view PHIO as a speculative opportunity with considerable upside potential.
• Investors should closely monitor the company's cash burn rate and potential for future financing, as the current strong balance sheet will be tested by the long and costly clinical development timeline extending into 2026.
• Key inflection points to watch are interim data from the ongoing dose escalation cohorts and any updates on the trial enrollment timeline, as these will be primary drivers of valuation ahead of the next major data release.
• The inherent risks of a micro-cap, single-product biotech company remain high, including the possibility of clinical trial failure or future shareholder dilution, warranting careful position sizing.